Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
BACKGROUND
This study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant.


METHODS
A 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes.


METHODS
Both eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially.


RESULTS
Vision improved significantly in both eyes. There were no evident pregnancy-related complications at 1 year postpartum.


CONCLUSIONS
Although anti-vascular endothelial growth factor (VEGF) therapy did not result in any detectable short-term adverse event in this mother and baby, the potential toxicity of these agents must be carefully considered in pregnant patients.
Wu
Ziqiang
Z
Center for Advanced Eye Care, Carson City, NV 89703, USA. ziqiangw@hotmail.com
Huang
Jingjing
J
Sadda
Srinivas
S
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab